{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(1)"],"submitter":["Kumar A"],"pubmed_abstract":["LC-MS and immunoassay can detect protein biomarkers. Immunoassays are more commonly used but can potentially be outperformed by LC-MS. These techniques have limitations including the necessity to generate separate calibration curves for each biomarker. We present a rapid mass spectrometry-based assay utilising a universal calibration curve. For the first time we analyse clinical samples using the HeavyPeptide IGNIS kit which establishes a 6-point calibration curve and determines the biomarker concentration in a single LC-MS acquisition. IGNIS was tested using apolipoprotein F (APO-F), a potential biomarker for non-alcoholic fatty liver disease (NAFLD). Human serum and IGNIS prime peptides were digested and the IGNIS assay was used to quantify APO-F in clinical samples. Digestion of IGNIS p"],"journal":["Scientific reports"],"pagination":["12072"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5608892"],"repository":["biostudies-literature"],"pubmed_title":["Absolute quantitation of disease protein biomarkers in a single LC-MS acquisition using apolipoprotein F as an example."],"pmcid":["PMC5608892"],"pubmed_authors":["Cobbold J","Zitzmann N","Thursz M","Kumar A","Gangadharan B"],"additional_accession":[]},"is_claimable":false,"name":"Absolute quantitation of disease protein biomarkers in a single LC-MS acquisition using apolipoprotein F as an example.","description":"LC-MS and immunoassay can detect protein biomarkers. Immunoassays are more commonly used but can potentially be outperformed by LC-MS. These techniques have limitations including the necessity to generate separate calibration curves for each biomarker. We present a rapid mass spectrometry-based assay utilising a universal calibration curve. For the first time we analyse clinical samples using the HeavyPeptide IGNIS kit which establishes a 6-point calibration curve and determines the biomarker concentration in a single LC-MS acquisition. IGNIS was tested using apolipoprotein F (APO-F), a potential biomarker for non-alcoholic fatty liver disease (NAFLD). Human serum and IGNIS prime peptides were digested and the IGNIS assay was used to quantify APO-F in clinical samples. Digestion of IGNIS p","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Sep","modification":"2026-05-06T06:32:42.094Z","creation":"2019-03-27T02:57:04Z"},"accession":"S-EPMC5608892","cross_references":{"pubmed":["28935895"],"doi":["10.1038/s41598-017-12229-2"]}}